MedTrace Logo

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

NCT01364727 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for thymic cancers.

Conditions

  • Thymoma
  • Thymus Cancer
  • Thymic Carcinoma

Interventions

DRUG

Amrubicin

35 mg/m2; IV on days 1-3 each 3 week cycle

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Heather Wakelee

    lead OTHER

Principal Investigators

  • Heather A. Wakelee · Stanford University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-07-31
Completion
2018-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01364727 on ClinicalTrials.gov